Karyopharm Therapeutics (KPTI) FCF Margin (2012 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly FCF Margin came in at 34.71% in Q4 2025, up 4963.0% YoY from 0.69% in Q4 2024, and down 160.86% on a QoQ basis from 13.3% in Q3 2025.
Karyopharm Therapeutics (KPTI) FCF Margin (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of FCF Margin data on file, last reported at 34.71% in Q4 2025.
- Quarterly FCF Margin rose 4963.0% year-over-year to 34.71% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 51.6% (up 3628.0% YoY) and the FY2025 annual result came in at 51.6%, up 3628.0% from the prior year.
- FCF Margin retreated to 34.71% in Q4 2025, from 13.3% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 20.01% in Q4 2021 to a low of 246.66% in Q2 2021.
- A 5-year average of 86.38% and a median of 79.27% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2021 — FCF Margin slumped 12643 bps — and 2022, when it surged 15809 bps.
- Tracing KPTI's FCF Margin over 5 years: stood at 20.01% in 2021, then sank by 499 bps to 79.94% in 2022, then soared by 31 bps to 55.07% in 2023, then tumbled by 53 bps to 84.33% in 2024, then jumped by 59 bps to 34.71% in 2025.
- The last three FCF Margin figures came in at 34.71% (Q4 2025), 13.3% (Q3 2025), and 49.29% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34.71% |
| Sep 30, 2025 | -13.30% |
| Jun 30, 2025 | -49.29% |
| Mar 31, 2025 | -129.88% |
| Dec 31, 2024 | -84.33% |
| Sep 30, 2024 | -50.16% |
| Jun 30, 2024 | -89.98% |
| Mar 31, 2024 | -132.58% |
| Dec 31, 2023 | -55.07% |
| Sep 30, 2023 | -82.01% |
| Jun 30, 2023 | -68.38% |
| Mar 31, 2023 | -48.87% |
| Dec 31, 2022 | -79.94% |
| Sep 30, 2022 | -78.60% |
| Jun 30, 2022 | -88.57% |
| Mar 31, 2022 | -124.35% |
| Dec 31, 2021 | 20.01% |
| Sep 30, 2021 | -63.57% |
| Jun 30, 2021 | -246.66% |
| Mar 31, 2021 | -227.38% |